Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Brevimytal Natrium
2. Brevital
3. Brietal
4. Brietal Sodium
5. Brietal-sodium
6. Methohexital Sodium
7. Methohexital, Monosodium Salt
8. Methohexitone
9. Monosodium Salt Methohexital
10. Natrium, Brevimytal
11. Sodium, Methohexital
1. Methohexitone
2. 151-83-7
3. Methodrexitone
4. Enallynymall
5. Methohexitalum
6. Metohexital
7. Brietal
8. 5-allyl-5-(3-hexyn-2-yl)-1-methylbarbituric Acid
9. Compound 22451
10. Compound 25398
11. 18652-93-2
12. (+-)-5-allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric Acid
13. 5-hex-3-yn-2-yl-1-methyl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
14. Chebi:102216
15. 5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1h,3h,5h)-pyrimidinetrione
16. E5b8nd5ipe
17. Metoesital
18. 5-allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione
19. Enallynymalum
20. Barbituric Acid, 5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-
21. Alpha-dl-1-methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituric Acid
22. Metoesital [dcit]
23. (+/-)-5-allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric Acid
24. .alpha.-dl-1-methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituric Acid
25. Barbituric Acid, 5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-, (.+/-.)-
26. Metohexital [inn-spanish]
27. Dea No. 2264
28. Methohexitalum [inn-latin]
29. Methohexital (usp/inn)
30. Unii-e5b8nd5ipe
31. Methohexital [usp:inn:ban]
32. Methohexital Civ
33. Einecs 205-798-6
34. Methohexital [mi]
35. Methohexital [inn]
36. Epitope Id:117125
37. Chembl7413
38. Methohexital [vandf]
39. Schembl80729
40. Methohexital [mart.]
41. Methohexital [who-dd]
42. Gtpl7233
43. Dtxsid1023287
44. Methohexital Civ [usp-rs]
45. Act02624
46. Methohexital [usp Monograph]
47. Methohexital 1.0 Mg/ml In Methanol
48. 5-allyl-5-(hex-3-yn-2-yl)-1-methylpyrimidine-2,4,6(1h,3h,5h)-trione
49. Db00474
50. 1-methyl-5-(1-methylpent-2-yn-1-yl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1h,3h,5h)-trione
51. 1-methyl-5-(1-methylpent-2-yn-1-yl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1h,3h,5h)-trione
52. 2,4,6(1h,3h,5h)-pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-
53. 5-(hex-3-yn-2-yl)-1-methyl-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione
54. 2,4,6(1h,3h,5h)-pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-, (+/-)-
55. Bm164664
56. Db-043117
57. C07844
58. D04985
59. A809228
60. Q851813
61. 1-methyl-5-(1-methyl-2-pentynyl)-5-allyl-barbituric Acid
62. Dl-1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-2,4,6(1h,3h,5h)-pyrimidinetrione
63. 2,4(3h,5h)-pyrimidinedione, 6-hydroxy-3-methyl-5-(1-methyl-2-pentyn-1-yl)-5-(2-propen-1-yl)-
64. 2,4,6(1h,3h,5h)-pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-, (+-)-
65. 2,4,6(1h,3h,5h)-pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-, (.+/-.)-
66. 5-(hex-3-yn-2-yl)-6-hydroxy-3-methyl-5-(prop-2-en-1-yl)-2,3,4,5-tetrahydropyrimidine-2,4-dione
Molecular Weight | 262.30 g/mol |
---|---|
Molecular Formula | C14H18N2O3 |
XLogP3 | 2.3 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 3 |
Exact Mass | 262.13174244 g/mol |
Monoisotopic Mass | 262.13174244 g/mol |
Topological Polar Surface Area | 66.5 Ų |
Heavy Atom Count | 19 |
Formal Charge | 0 |
Complexity | 497 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 2 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Methohexital is indicated for use as an intravenous anaesthetic. It has also been commonly used to induce deep sedation.
FDA Label
Methohexital, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.
Anesthetics, Intravenous
Ultrashort-acting anesthetics that are used for induction. Loss of consciousness is rapid and induction is pleasant, but there is no muscle relaxation and reflexes frequently are not reduced adequately. Repeated administration results in accumulation and prolongs the recovery time. Since these agents have little if any analgesic activity, they are seldom used alone except in brief minor procedures. (From AMA Drug Evaluations Annual, 1994, p174) (See all compounds classified as Anesthetics, Intravenous.)
N - Nervous system
N01 - Anesthetics
N01A - Anesthetics, general
N01AF - Barbiturates, plain
N01AF01 - Methohexital
N - Nervous system
N05 - Psycholeptics
N05C - Hypnotics and sedatives
N05CA - Barbiturates, plain
N05CA15 - Methohexital
Absorption
The absolute bioavailability following rectal administration of methohexital is 17%.
Route of Elimination
Excretion occurs via the kidneys through glomerular filtration.
Metabolism occurs in the liver through demethylation and oxidation. Side-chain oxidation is the most important biotransformation involved in termination of biologic activity.
5.6 ± 2.7 minutes
Methohexital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A METHOHEXITAL SODIUM manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of METHOHEXITAL SODIUM, including repackagers and relabelers. The FDA regulates METHOHEXITAL SODIUM manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. METHOHEXITAL SODIUM API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of METHOHEXITAL SODIUM manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A METHOHEXITAL SODIUM supplier is an individual or a company that provides METHOHEXITAL SODIUM active pharmaceutical ingredient (API) or METHOHEXITAL SODIUM finished formulations upon request. The METHOHEXITAL SODIUM suppliers may include METHOHEXITAL SODIUM API manufacturers, exporters, distributors and traders.
click here to find a list of METHOHEXITAL SODIUM suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A METHOHEXITAL SODIUM DMF (Drug Master File) is a document detailing the whole manufacturing process of METHOHEXITAL SODIUM active pharmaceutical ingredient (API) in detail. Different forms of METHOHEXITAL SODIUM DMFs exist exist since differing nations have different regulations, such as METHOHEXITAL SODIUM USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A METHOHEXITAL SODIUM DMF submitted to regulatory agencies in the US is known as a USDMF. METHOHEXITAL SODIUM USDMF includes data on METHOHEXITAL SODIUM's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The METHOHEXITAL SODIUM USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of METHOHEXITAL SODIUM suppliers with USDMF on PharmaCompass.
A METHOHEXITAL SODIUM written confirmation (METHOHEXITAL SODIUM WC) is an official document issued by a regulatory agency to a METHOHEXITAL SODIUM manufacturer, verifying that the manufacturing facility of a METHOHEXITAL SODIUM active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting METHOHEXITAL SODIUM APIs or METHOHEXITAL SODIUM finished pharmaceutical products to another nation, regulatory agencies frequently require a METHOHEXITAL SODIUM WC (written confirmation) as part of the regulatory process.
click here to find a list of METHOHEXITAL SODIUM suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing METHOHEXITAL SODIUM as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for METHOHEXITAL SODIUM API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture METHOHEXITAL SODIUM as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain METHOHEXITAL SODIUM and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a METHOHEXITAL SODIUM NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of METHOHEXITAL SODIUM suppliers with NDC on PharmaCompass.
METHOHEXITAL SODIUM Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of METHOHEXITAL SODIUM GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right METHOHEXITAL SODIUM GMP manufacturer or METHOHEXITAL SODIUM GMP API supplier for your needs.
A METHOHEXITAL SODIUM CoA (Certificate of Analysis) is a formal document that attests to METHOHEXITAL SODIUM's compliance with METHOHEXITAL SODIUM specifications and serves as a tool for batch-level quality control.
METHOHEXITAL SODIUM CoA mostly includes findings from lab analyses of a specific batch. For each METHOHEXITAL SODIUM CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
METHOHEXITAL SODIUM may be tested according to a variety of international standards, such as European Pharmacopoeia (METHOHEXITAL SODIUM EP), METHOHEXITAL SODIUM JP (Japanese Pharmacopeia) and the US Pharmacopoeia (METHOHEXITAL SODIUM USP).
LOOKING FOR A SUPPLIER?